Clinical Trial Update: ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cenicriviroc on insulin sensitivity in people with prediabetes or type 2 diabetes and suspected non-alcoholic fatty liver disease has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Prediabetic State
• Type 2 Diabetes Mellitus

Drugs mentioned

• Cenicriviroc (cenicriviroc)

Snippet

Sponsor: Tobira Therapeutics, Inc. | Conditions: Prediabetic State, Non-alcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED | Results posted: 2019-10-11